BlackRock Amends Ultragenyx Stake, Maintains Significant Position
Ticker: RARE · Form: SC 13G/A · Filed: Jan 29, 2024 · CIK: 1515673
| Field | Detail |
|---|---|
| Company | Ultragenyx Pharmaceutical Inc. (RARE) |
| Form Type | SC 13G/A |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, beneficial-ownership
TL;DR
**BlackRock still owns a big chunk of Ultragenyx, signaling continued institutional confidence.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 29, 2024, disclosing its ownership of Ultragenyx Pharmaceutical Inc. common stock as of December 31, 2023. This filing indicates that BlackRock, a major institutional investor, continues to hold a significant stake in Ultragenyx, signaling its ongoing confidence in the pharmaceutical company. For investors, this means a large, influential fund manager sees value in Ultragenyx, which can be a positive indicator for the stock's stability and future prospects.
Why It Matters
This filing shows that a major institutional investor, BlackRock, continues to hold a substantial position in Ultragenyx, which can reassure current and potential investors about the stock's long-term viability.
Risk Assessment
Risk Level: low — This filing indicates a stable institutional ownership, which generally reduces volatility and risk for the stock.
Analyst Insight
Investors should note BlackRock's continued institutional ownership as a sign of stability, but also research Ultragenyx's fundamentals and recent performance to make informed decisions, as this filing primarily confirms existing ownership rather than new investment.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- Ultragenyx Pharmaceutical Inc. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 29, 2024 (date) — the filing date of the SC 13G/A
- 90400D108 (other) — the CUSIP number for Ultragenyx Pharmaceutical Inc. common stock
Forward-Looking Statements
- BlackRock will likely maintain a significant stake in Ultragenyx Pharmaceutical Inc. throughout 2024, given their continued reporting of beneficial ownership. (BlackRock Inc.) — medium confidence, target: 2024-12-31
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, indicating a change or update to a previously reported beneficial ownership stake.
Who is the reporting person in this filing?
The reporting person is BlackRock Inc., a major asset management firm, as stated under 'Names of reporting persons. BlackRock, Inc.'
What is the subject company of this filing?
The subject company is Ultragenyx Pharmaceutical Inc., as indicated by 'Name of Issuer) ULTRAGENYX PHARMACEUTICAL INC'.
What is the CUSIP number for the securities reported?
The CUSIP number for the common stock of Ultragenyx Pharmaceutical Inc. is 90400D108, as listed under 'CUSIP No. 90400D108'.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023, as specified in the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 29, 2024 regarding Ultragenyx Pharmaceutical Inc. (RARE).